{
    "elements": [
        {
            "type": "image",
            "sequence_num": 1,
            "data": {
                "url": "MSEPO-20204 Safe Handling Effective Use and Management of IMPs 1.0.001.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 2,
            "data": {
                "num_rows": 15,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Title:"
                    },
                    {
                        "text": "Policy on the Safe Handling, Effective Use and Management of Investigational Medicinal Products (Imps)"
                    },
                    {
                        "text": "Document Reference/Register no:"
                    },
                    {
                        "text": "MSEP-20204"
                    },
                    {
                        "text": "Version Number:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Document type: (Policy/ Guideline/ SOP)"
                    },
                    {
                        "text": "Policy"
                    },
                    {
                        "text": "To be followed by: (Target Staff)"
                    },
                    {
                        "text": "All staff who are directly involved with the management of clinical trial medication or those who handle clinical trial medication in some way from the point of receipt to the point of patient administration."
                    },
                    {
                        "text": "Ratification Issue Date: (Date document is uploaded onto the intranet)"
                    },
                    {
                        "text": "rd 3 March 2020"
                    },
                    {
                        "text": "Review Date:"
                    },
                    {
                        "text": "nd2 March 2023"
                    },
                    {
                        "text": "Developed in response to:"
                    },
                    {
                        "text": "Medicines for Human Use (Clinical Trials) Regulations 2004 MHRA (Medicines and Healthcare products Regulatory Authority) NPCTAG (National Pharmacy Clinical Trials Advisory Group)"
                    },
                    {
                        "text": "Contributes to HSC Act 2008 (Regulated Activities) Regulations 2014(Part 3); and CQC Regulations 2009 (Part 4) CQC Fundamental Standards of Quality and Safety:"
                    },
                    {
                        "text": "Regulation 12: Safe care and treatment"
                    },
                    {
                        "text": "Issuing Division/Directorate:"
                    },
                    {
                        "text": "Pharmacy"
                    },
                    {
                        "text": "Author/Contact: (Asset Administrator)"
                    },
                    {
                        "text": "Emma Cannon - Lead Pharmacist Clinical Trials (MEHT)"
                    },
                    {
                        "text": "Hospital Sites: (tick appropriate box/es to indicate status of policy review i.e. joint/ independent)"
                    },
                    {
                        "text": "Mid Essex Hospital Services NHS Trust (MEHT) Basildon and Thurrock University Hospitals NHS Foundation Trust (BTUH) \uf0fcSouthend University Hospital NHS Foundation Trust (SUHT)"
                    },
                    {
                        "text": "Consultation:"
                    },
                    {
                        "text": "(Refer to page 2)"
                    },
                    {
                        "text": "Approval Group / Committee(s):"
                    },
                    {
                        "text": "Medicines Management Committee (SUH/BTUH) Medicines Optimisation and Safety Group (MEHT)"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "31/01/2020 07/02/2020"
                    },
                    {
                        "text": "Professionally Approved by: (Asset Owner)"
                    },
                    {
                        "text": "Evelyn Allen Group Chief Pharmacist"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "07/02/2020"
                    },
                    {
                        "text": "Ratification Group(s):"
                    },
                    {
                        "text": "Joint Document Management Group"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "18.02.2020"
                    },
                    {
                        "text": "Executive and Clinical Directors (Communication of minutes from Document Ratification Group"
                    },
                    {
                        "text": "Date: February 2020"
                    },
                    {
                        "text": "Distribution Method:"
                    },
                    {
                        "text": "Trust Intranet/ Internet"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 3,
            "data": {
                "url": "MSEPO-20204 Safe Handling Effective Use and Management of IMPs 1.0.002.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 4,
            "data": {
                "num_rows": 9,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Consulted With: this must include Pharmacy if the document has any reference to medication"
                    },
                    {
                        "text": "Post/ Approval Committee/ Group:"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "Felix Lo"
                    },
                    {
                        "text": "Clinical Trials Pharmacist BTUH"
                    },
                    {
                        "text": "04.07.19"
                    },
                    {
                        "text": "Usha Ravichandran"
                    },
                    {
                        "text": "Clinical Trials Pharmacist SUH"
                    },
                    {
                        "text": "04.07.19"
                    },
                    {
                        "text": "Tracey Camburn"
                    },
                    {
                        "text": "Lead Research Nurse and Director of Research and Development MEHT"
                    },
                    {
                        "text": "25.11.19"
                    },
                    {
                        "text": "Ashley Solieri"
                    },
                    {
                        "text": "Associate Director, Research and Development BTUH"
                    },
                    {
                        "text": "28.11.19"
                    },
                    {
                        "text": "Jo Calver"
                    },
                    {
                        "text": "Clinical Trials Assistant, Research and Development department SUH"
                    },
                    {
                        "text": "29.11.19"
                    },
                    {
                        "text": "Sharon Tysoe"
                    },
                    {
                        "text": "Stroke Research Nurse SUH"
                    },
                    {
                        "text": "29.11.19"
                    },
                    {
                        "text": "This has been consulted by all clinical trial groups on all sites. As this principally covers the medication aspects these are standard and there is no new requirements as such, just clarifying them in policy where was not previously."
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "19/02/2020"
                    },
                    {
                        "text": "Ashley Solieri Head of Research for MSE Group"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "20.02.2020"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 5,
            "data": {
                "num_rows": 1,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Related Trust Policies (to be read in conjunction with)"
                    },
                    {
                        "text": "All Medicines Management Policies on all sites, especially: Policy for Administration of Medicines (or equivalent), Injectable Medicine Policy (or equivalent), Cytotoxic Medicines Policy (or equivalent). All MSE Clinical Trial Standard Operating Procedures Relevant Research & Development Standard Operating Procedures"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 6,
            "data": {
                "num_rows": 8,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Review History:"
                    },
                    {
                        "text": "Version No:"
                    },
                    {
                        "text": "Authored/Reviewer:"
                    },
                    {
                        "text": "Summary of amendments/ Record documents superseded by:"
                    },
                    {
                        "text": "Issue Date:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Emma Cannon"
                    },
                    {
                        "text": "Replaces SUH MMP028 Safe Handling, Effective Use of IMPs. New policy for BTUH and MEHT. Amended for MSE-wide use."
                    },
                    {
                        "text": "3rd March 2020"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "text": "Contents"
            },
            "type": "ListItem",
            "sequence_num": 7
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "Introduction ................................................................................................................. 4"
            },
            "type": "ListItem",
            "sequence_num": 8
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "Scope ........................................................................................................................... 4"
            },
            "type": "ListItem",
            "sequence_num": 9
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Definitions ................................................................................................................... 5"
            },
            "type": "ListItem",
            "sequence_num": 10
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Roles and Responsibilities ........................................................................................ 6"
            },
            "type": "ListItem",
            "sequence_num": 11
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "Good Clinical Practice (GCP) .................................................................................. 10"
            },
            "type": "ListItem",
            "sequence_num": 12
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "Pharmacy Facilities .................................................................................................. 10"
            },
            "type": "ListItem",
            "sequence_num": 13
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Pharmacy Service and Resources .......................................................................... 11"
            },
            "type": "ListItem",
            "sequence_num": 14
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 8.0,
                "text": "Prescription Charges ............................................................................................... 12"
            },
            "type": "ListItem",
            "sequence_num": 15
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 9.0,
                "text": "Communication Within and Outside the Trust ....................................................... 12 10 Set-up of a study ....................................................................................................... 12 11 Approvals .................................................................................................................. 14 12 IMP Management ...................................................................................................... 14 13 Receipt/delivery of IMP to pharmacy ...................................................................... 14 14 Prescribing of IMP .................................................................................................... 14 15 Supply of IMP from pharmacy ................................................................................. 15 16 Administering ........................................................................................................... 15 17 Safety Monitoring ..................................................................................................... 16 18 Incident Reporting .................................................................................................... 17 19 Training Requirements ............................................................................................. 17 20 Monitoring and Audit ................................................................................................ 17 21 Approval and Implementation ................................................................................. 18 22 References ................................................................................................................ 18 23 Equality Impact Assessment ................................................................................... 18 Appendix 1: Preliminary Equality Analysis ................................................................... 19"
            },
            "type": "ListItem",
            "sequence_num": 16
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Safe Handling, Effective Use and Management of Investigational Medicinal Products (IMPs) Policy/ MSEPO- 20204 / version 1.0"
            },
            "type": "ListItem",
            "sequence_num": 17
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 23.0,
                "text": "Page  of"
            },
            "type": "ListItem",
            "sequence_num": 18
        },
        {
            "data": {
                "is_heading": 1,
                "text": "This is an uncontrolled copy of this policy. To check if this is a copy of the latest version please view this policy on-line on StaffNet"
            },
            "type": "ListItem",
            "sequence_num": 19
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "Introduction"
            },
            "type": "ListItem",
            "sequence_num": 20
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "This policy is intended for use by pharmacy staff involved with the provision of clinical trials services at policy, strategic and operational levels."
            },
            "type": "ListItem",
            "sequence_num": 21
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.2,
                "text": "It applies to all clinical trials that are regulated by the Medicines for Human Use (Clinical Trials) Regulations 2004 and subsequent amendments. This includes commercial and non-commercial clinical trials."
            },
            "type": "ListItem",
            "sequence_num": 22
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.3,
                "text": "It does not specifically relate to pharmacy practice research unless this involves a Clinical Trial of an Investigational Medicinal Product (CTIMP)."
            },
            "type": "ListItem",
            "sequence_num": 23
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.4,
                "text": "The policy relates to the medicines management of Investigational Medicinal Products (IMPs), facilities required for the support of clinical trials services in accordance with regulatory requirements and informs operational, strategic and policy decisions relating to IMPs. It is underpinned by the principles of Good Clinical Practice (GCP) for the management of IMPs."
            },
            "type": "ListItem",
            "sequence_num": 24
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.5,
                "text": "This policy also relates to non CTIMP trials where medication is involved in a capacity such as support medication or where the medication itself is not the subject of the trial intervention."
            },
            "type": "ListItem",
            "sequence_num": 25
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.6,
                "text": "Pharmacy may be required to support clinical trials involving medicines, biological substances, gene therapy or radiopharmaceuticals. Specific guidance and regulations exist for the management of these products and before embarking on a clinical trial, it is the responsibility of the pharmacy staff involved to ensure working knowledge of all aspects of guidance and regulatory documents and compliance thereof. It may not be appropriate for a given site to participate in a particular type of clinical trial and it is therefore essential that pharmacy have involvement in/knowledge of a potential clinical trial from the feasibility stage."
            },
            "type": "ListItem",
            "sequence_num": 26
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.7,
                "text": "All IMPs should be stored and dispensed by the hospital pharmacy and managed to the same standards as licensed medicines, in accordance with the Trust medicines management policies."
            },
            "type": "ListItem",
            "sequence_num": 27
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "Scope"
            },
            "type": "ListItem",
            "sequence_num": 28
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 2.1,
                "text": "The purpose of this document is to summarise the processes to be followed to ensure the safe handling of medications in clinical trials."
            },
            "type": "ListItem",
            "sequence_num": 29
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 2.2,
                "text": "The Pharmacy Clinical Trials Service works to their own set of approved SOPs for every step and every task in clinical trial investigational medicinal product (CTIMP) management."
            },
            "type": "ListItem",
            "sequence_num": 30
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 2.3,
                "text": "The roles and responsibilities of pharmacy and pharmacy staff are set out to ensure pharmacy has knowledge of and involvement in all aspects of CTIMPs so as to safeguard subjects, health care professionals and the Trust."
            },
            "type": "ListItem",
            "sequence_num": 31
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Definitions"
            },
            "type": "ListItem",
            "sequence_num": 32
        },
        {
            "type": "table",
            "sequence_num": 33,
            "data": {
                "num_rows": 10,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "TERM"
                    },
                    {
                        "text": "DEFINITION"
                    },
                    {
                        "text": "Clinical Trial Authorisation (CTA):"
                    },
                    {
                        "text": "Authorisation given by the competent authority (The MHRA in the UK) to conduct a clinical trial."
                    },
                    {
                        "text": "cTAG"
                    },
                    {
                        "text": "Clinical trial agreement (used in commercial clinical trials)."
                    },
                    {
                        "text": "Clinical Trial of an Investigational Medicinal product (CTIMP):"
                    },
                    {
                        "text": "An investigation in human subjects intended to \u2018discover or verify the clinical, pharmacological or other pharmacodynamic effects of one or more medicinal products, to identify any adverse reactions to one or more such products, or to study absorption, distribution, metabolism, and excretion of one or more such products, with the object of ascertaining the safety or efficacy of those products' (Regulation 2 of SI 2004/1031)."
                    },
                    {
                        "text": "Clinical Trial Protocol:"
                    },
                    {
                        "text": "A document that describes the objective(s), design, methodology, statistical considerations, and organisation of that trial. The protocol usually also gives the background and rationale for the trial but these could be provided in other protocol reference documents."
                    },
                    {
                        "text": "EEA"
                    },
                    {
                        "text": "European Economic Area."
                    },
                    {
                        "text": "Good Clinical Practice (GCP):"
                    },
                    {
                        "text": "A set of internationally recognised ethical and scientific quality requirements that must be observed for designing, conducting, recording and reporting clinical trials that involve the participation of human subjects. Compliance with this good practice provides assurance that the rights, safety and well- being of trial subjects are protected, and that the results of the clinical trials are credible and accurate. (EU Directive 2001/20/EC)."
                    },
                    {
                        "text": "Good Manufacturing Practice (GMP):"
                    },
                    {
                        "text": "The part of quality assurance which ensures that medicinal products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorisation or product specification. GMP is concerned with both production and quality control."
                    },
                    {
                        "text": "Health Research Authority (HRA):"
                    },
                    {
                        "text": "The authority whose purpose it is to protect and promote the interests of patients and the public in health and social care research. This includes ensuring research is ethically reviewed and approved."
                    },
                    {
                        "text": "Investigational Medicinal Product (IMP):"
                    },
                    {
                        "text": "A pharmaceutical form of an active substance or placebo being tested or used as a reference product in a clinical trial. IMPs can include authorised products in their approved form, either within or outside their licensed indication, or manufactured and"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 34,
            "data": {
                "num_rows": 11,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": ""
                    },
                    {
                        "text": "assembled (formulated or packaged) in a way that is different from the authorised form."
                    },
                    {
                        "text": "Investigator:"
                    },
                    {
                        "text": "An authorised healthcare professional responsible for the conduct of the clinical trial at a clinical trial site. If a trial is conducted by a team of authorised health professionals at a trial site, the investigator is the leader responsible for that team."
                    },
                    {
                        "text": "Medicines and Healthcare products Regulatory Agency (MHRA):"
                    },
                    {
                        "text": "The government agency which is responsible for ensuring that medicines and medical devices work, and are acceptably safe."
                    },
                    {
                        "text": "NIHR"
                    },
                    {
                        "text": "National Institute for Health Research"
                    },
                    {
                        "text": "Non- Investigational Medicinal Product (nIMP):"
                    },
                    {
                        "text": "Products which are not the object of investigation (other than the tested product, placebo or active comparator) may be supplied to subjects participating in a trial and used in accordance with the protocol. E.g. support or rescue/escape medication for preventive, diagnostic or therapeutic reasons and/or to ensure that adequate medical care is provided for the subject."
                    },
                    {
                        "text": "QP"
                    },
                    {
                        "text": "Qualified Person (in context of MHRA and associated regulations)"
                    },
                    {
                        "text": "REC"
                    },
                    {
                        "text": "Research Ethics Committee"
                    },
                    {
                        "text": "R&D"
                    },
                    {
                        "text": "Research and Development"
                    },
                    {
                        "text": "SACT"
                    },
                    {
                        "text": "Systemic Anti-cancer Therapy"
                    },
                    {
                        "text": "SOP"
                    },
                    {
                        "text": "Standard Operating Procedure"
                    },
                    {
                        "text": "Sponsor:"
                    },
                    {
                        "text": "A sponsor is, in relation to a clinical trial, a person/organisation who takes responsibility for the initiation, management and financing (or arranging the financing) of that clinical trial."
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Roles and Responsibilities"
            },
            "type": "ListItem",
            "sequence_num": 35
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.1,
                "text": "The Trust Board is responsible for acknowledging and making decisions in response to Chief Pharmacist reports pertaining to Medicines Optimisation for the organisation."
            },
            "type": "ListItem",
            "sequence_num": 36
        },
        {
            "data": {
                "is_heading": 1,
                "text": "4.1.1 Site or Group Risk & Compliance Group (or equivalent) is responsible for acknowledging and making decisions pertaining to exception reporting received from the MOC or Site MOSG."
            },
            "type": "ListItem",
            "sequence_num": 37
        },
        {
            "data": {
                "is_heading": 1,
                "text": "4.1.2 Medicines Optimisation Committee (MOC) (or equivalent) (group-wide)  Responsible for:"
            },
            "type": "ListItem",
            "sequence_num": 38
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Acknowledging and making decisions where possible related to service delivery."
            },
            "type": "ListItem",
            "sequence_num": 39
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Escalating any medication-related clinical trial issues, as relevant to the site Risk and Compliance Group (or equivalent)."
            },
            "type": "ListItem",
            "sequence_num": 40
        },
        {
            "data": {
                "is_heading": 1,
                "text": "4.1.3 Site Medicines Optimisation and Safety Group (MOSG) (or equivalent) is responsible for managing medication-related clinical trial issues in conjunction with relevant Research and Development corporate groups."
            },
            "type": "ListItem",
            "sequence_num": 41
        },
        {
            "data": {
                "is_heading": 1,
                "text": "4.1.4 Pharmacy Directorate Board (PB) (group-wide)"
            },
            "type": "ListItem",
            "sequence_num": 42
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Responsible for:"
            },
            "type": "ListItem",
            "sequence_num": 43
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Taking action with respect to pharmacy service delivery."
            },
            "type": "ListItem",
            "sequence_num": 44
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Safeguarding subjects, healthcare professionals, and the Trust by ensuring that IMPs are appropriate for use and are procured, handled, stored and used safely and correctly."
            },
            "type": "ListItem",
            "sequence_num": 45
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring pharmacy staff have undertaken GCP and any clinical trial specific training according to protocol prior to handling or carrying out trial specific procedures."
            },
            "type": "ListItem",
            "sequence_num": 46
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring pharmacy has given input into the costing and review of cTAG prior to final agreement."
            },
            "type": "ListItem",
            "sequence_num": 47
        },
        {
            "data": {
                "is_heading": 1,
                "text": "4.1.5 SACT Group (group-wide or site depending on trial need) is responsible for: the approval of clinical trial involving SACT."
            },
            "type": "ListItem",
            "sequence_num": 48
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.2,
                "text": "Chief Executive as the Trust Accountable Officer has overall responsibility for ensuring the MSE group of hospitals has robust, complete and up to date procedures in place to govern and guide activities so that legal and national requirements are met."
            },
            "type": "ListItem",
            "sequence_num": 49
        },
        {
            "data": {
                "is_heading": 1,
                "text": "4.2.1 Chief Medical Officer is responsible for ensuring that there is policy compliance operating consistently across all sites by all IMP investigators."
            },
            "type": "ListItem",
            "sequence_num": 50
        },
        {
            "data": {
                "is_heading": 1,
                "text": "4.2.2 Chief Nursing Officer (including delegation to Site Directors of Nursing) is"
            },
            "type": "ListItem",
            "sequence_num": 51
        },
        {
            "data": {
                "is_heading": 0,
                "text": "responsible for ensuring that there is policy compliance, operating consistently across all sites, for all professions they oversee who administer IMP to patients."
            },
            "type": "ListItem",
            "sequence_num": 52
        },
        {
            "data": {
                "is_heading": 1,
                "text": "4.2.3 Group Chief Pharmacist (Director of Pharmacy) is responsible for"
            },
            "type": "ListItem",
            "sequence_num": 53
        },
        {
            "data": {
                "is_heading": 0,
                "text": "having overall responsibility for establishing and changing medication use systems across the organisation."
            },
            "type": "ListItem",
            "sequence_num": 54
        },
        {
            "data": {
                "is_heading": 1,
                "text": "4.2.4 Deputy Chief Pharmacist (Site Lead) Responsible for:"
            },
            "type": "ListItem",
            "sequence_num": 55
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Leadership support to the Lead Pharmacist for Clinical Trials (or equivalent);"
            },
            "type": "ListItem",
            "sequence_num": 56
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Responding to escalated issues as appropriate from the site pharmacy clinical trials team;"
            },
            "type": "ListItem",
            "sequence_num": 57
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring pharmacy staff job descriptions provide clarity with regard to responsibility and accountability for clinical trials;"
            },
            "type": "ListItem",
            "sequence_num": 58
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Providing support to enable relevant clinical trials training to be given to the wider pharmacy team in order to ensure the safe and effective management of IMP."
            },
            "type": "ListItem",
            "sequence_num": 59
        },
        {
            "data": {
                "is_heading": 1,
                "text": "4.2.5 Lead Pharmacist Clinical Trials (or equivalent) Responsible for:"
            },
            "type": "ListItem",
            "sequence_num": 60
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Overseeing and managing day-to-day operations of the pharmacy clinical trials service;"
            },
            "type": "ListItem",
            "sequence_num": 61
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Supporting designated clinical trials pharmacists in their role;"
            },
            "type": "ListItem",
            "sequence_num": 62
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring that IMPs are managed and dispensed to patients in accordance with the duly approved current clinical trial protocol and associated trial documents;"
            },
            "type": "ListItem",
            "sequence_num": 63
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring that all pharmacy clinical trials procedures comply with relevant guidelines and regulations;"
            },
            "type": "ListItem",
            "sequence_num": 64
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Holding training records and signature logs for those staff involved in clinical trial activity which should be readily available for inspection if required;"
            },
            "type": "ListItem",
            "sequence_num": 65
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Distributing up to date documentation prior to initiation and during the course of the trial. This includes all amendments to trials and associated approvals."
            },
            "type": "ListItem",
            "sequence_num": 66
        },
        {
            "data": {
                "is_heading": 1,
                "text": "4.2.6 Designated Clinical Trial Pharmacist (or equivalent)"
            },
            "type": "ListItem",
            "sequence_num": 67
        },
        {
            "data": {
                "is_heading": 0,
                "text": "4.2.6.1 Note for some sites this may be the same as Lead Pharmacist Clinical Trials."
            },
            "type": "ListItem",
            "sequence_num": 68
        },
        {
            "data": {
                "is_heading": 0,
                "text": "4.2.6.2 They are given delegated authority to manage the IMP by each Trial's Principal Investigator and will be listed on the delegation log for each clinical trial."
            },
            "type": "ListItem",
            "sequence_num": 69
        },
        {
            "data": {
                "is_heading": 0,
                "text": "4.2.6.3 They are the first point of contact within pharmacy when trials involving IMPs are under consideration by the Trust."
            },
            "type": "ListItem",
            "sequence_num": 70
        },
        {
            "data": {
                "is_heading": 0,
                "text": "4.2.6.4 They seek advice from other pharmacists in specialist therapeutic areas within the pharmacy team where appropriate."
            },
            "type": "ListItem",
            "sequence_num": 71
        },
        {
            "data": {
                "is_heading": 0,
                "text": "4.2.6.5 Responsible for:"
            },
            "type": "ListItem",
            "sequence_num": 72
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring non-clinical trial members of the pharmacy team \u2013 ward staff, dispensary staff, goods receiving staff, aseptic staff - are adequately qualified, trained and experienced to assume the relevant clinical trials responsibilities;"
            },
            "type": "ListItem",
            "sequence_num": 73
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring the GCP competence of pharmacy staff commensurate with their roles and responsibilities in relation to CTIMPs;"
            },
            "type": "ListItem",
            "sequence_num": 74
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring the clinical trials specific standard operating procedures are in place and up to date and that the clinical trials service is operating in accordance with these SOPs;"
            },
            "type": "ListItem",
            "sequence_num": 75
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring appropriate logs have been completed and signed for all staff participating in the dispensing and supply of IMPs (i.e. delegation log/authorised persons log/signature log/training log)."
            },
            "type": "ListItem",
            "sequence_num": 76
        },
        {
            "data": {
                "is_heading": 1,
                "text": "4.2.7 Research and Development Lead (or equivalent) Responsible for:"
            },
            "type": "ListItem",
            "sequence_num": 77
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring regular dialogue with the pharmacy clinical trials team is in place;"
            },
            "type": "ListItem",
            "sequence_num": 78
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring pharmacy has given input into the costing and review of cTAG prior to final agreement;"
            },
            "type": "ListItem",
            "sequence_num": 79
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Distributing up to date documentation prior to initiation and during the course of the trial. This includes all amendments to trials and associated approvals."
            },
            "type": "ListItem",
            "sequence_num": 80
        },
        {
            "data": {
                "is_heading": 1,
                "text": "4.2.8 Principal Investigator (PI) as overall responsibility for the study including the study drug and the study team ensuring adequate training for all staff delegated to work on the study, including the study drug medicine management."
            },
            "type": "ListItem",
            "sequence_num": 81
        },
        {
            "data": {
                "is_heading": 1,
                "text": "4.2.9 Doctor / Investigator Responsible for:"
            },
            "type": "ListItem",
            "sequence_num": 82
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring they only are involved in any way with the IMP where they are signed off as competent for that specific trial and in clinical trials generally;"
            },
            "type": "ListItem",
            "sequence_num": 83
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Prescribing IMPs correctly and safely in line with this policy and the Trust Policy for Prescribing of Medicines (or equivalent);"
            },
            "type": "ListItem",
            "sequence_num": 84
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Administering the IMP, in some cases, correctly and safely in line with this policy and the Trust Policy for Administration of Medicines (or equivalent) and all associated clinical trial procedures related to that IMP."
            },
            "type": "ListItem",
            "sequence_num": 85
        },
        {
            "data": {
                "is_heading": 1,
                "text": "4.2.10 Administering Practitioner (i.e. Registered Nurse) Responsible for:"
            },
            "type": "ListItem",
            "sequence_num": 86
        },
        {
            "data": {
                "is_heading": 1,
                "text": "4.2.11 Pharmacy Clinical Trial Dispenser & Pharmacy Final Accuracy Checker Responsible for:"
            },
            "type": "ListItem",
            "sequence_num": 87
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "Good Clinical Practice (GCP)"
            },
            "type": "ListItem",
            "sequence_num": 88
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.1,
                "text": "All Clinical Trials involving IMPs must be conducted according to the principles of GCP. These are outlined in articles 2 to 5 in the EU Directive 2005/28/EC."
            },
            "type": "ListItem",
            "sequence_num": 89
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.2,
                "text": "GCP is a legal requirement for all clinical trials involving investigational medicinal products (IMPs) in addition to the regulatory requirements in the UK (Medicines for Human Use) Clinical Trials regulations."
            },
            "type": "ListItem",
            "sequence_num": 90
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.3,
                "text": "Individual staff members should ensure GCP competence commensurate with their roles and responsibilities in relation to CTIMPs."
            },
            "type": "ListItem",
            "sequence_num": 91
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "Pharmacy Facilities"
            },
            "type": "ListItem",
            "sequence_num": 92
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 6.1,
                "text": "It is essential to ensure appropriate facilities are available before agreeing to support a clinical trial. This is assessed by the designated clinical trials pharmacist as part of the feasibility process."
            },
            "type": "ListItem",
            "sequence_num": 93
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 6.2,
                "text": "Facilities must be available that allow for IMPs to be stored separately from normal pharmacy stock in an area which is lockable and has access restricted to pharmacy staff."
            },
            "type": "ListItem",
            "sequence_num": 94
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 6.3,
                "text": "Licensed medicines (with a UK or EEA Marketing Authorisation) used as IMPs do not have to be stored separately as long as there is a process in place to ensure traceability."
            },
            "type": "ListItem",
            "sequence_num": 95
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 6.4,
                "text": "IMPs that are returned by patients or have expired are stored separately from unused IMPs."
            },
            "type": "ListItem",
            "sequence_num": 96
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 6.5,
                "text": "Quarantined medication is clearly identified and segregated from working stock."
            },
            "type": "ListItem",
            "sequence_num": 97
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 6.6,
                "text": "Facilities must be made available to enable segregated storage areas. The relevant site pharmacy clinical trial SOP details further specific instructions."
            },
            "type": "ListItem",
            "sequence_num": 98
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 6.7,
                "text": "Regular temperature monitoring of IMP storage facilities must be undertaken and records maintained."
            },
            "type": "ListItem",
            "sequence_num": 99
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 6.8,
                "text": "All IMP storage areas are fitted with calibrated temperature monitoring devices that record maximum and minimum temperatures; with a robust system to alert designated staff if the temperature falls outside of the specified range."
            },
            "type": "ListItem",
            "sequence_num": 100
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 6.9,
                "text": "Each temperature monitoring device must have a valid proof of calibration which is maintained for reference by the pharmacy clinical trials team."
            },
            "type": "ListItem",
            "sequence_num": 101
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 6.1,
                "text": "The specific clinical trial temperature monitoring SOP must be referred to for the action to follow when storage conditions are outside of the specified range."
            },
            "type": "ListItem",
            "sequence_num": 102
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 6.11,
                "text": "Some IMP's are required to be used in a trial for emergency or need out of hours access or it is deemed not appropriate/practical to store the IMP within pharmacy. In such cases a risk assessment is completed by the designated clinical trials pharmacist to ensure the proposed area is safe and secure. The risk assessment is clearly documented and if necessary discussed at the site Risk and Compliance Committee. Pharmacy and R&D teams collaborate to ensure the storage area complies with both trial protocol and Trust requirements."
            },
            "type": "ListItem",
            "sequence_num": 103
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 6.12,
                "text": "Suitable archiving facilities are required for pharmacy trial files, temperature monitoring documents, aseptic worksheets etc. The facility on each site allows for prompt retrieval of the required documents. The Pharmacy Site File is amalgamated back into the Investigator Site File for archiving purposes and liaison with the R&D Department is sought to arrange this."
            },
            "type": "ListItem",
            "sequence_num": 104
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Pharmacy Service and Resources"
            },
            "type": "ListItem",
            "sequence_num": 105
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 7.1,
                "text": "The Chief Pharmacist ensures that adequate resources are available to provide a pharmacy clinical trial service so that research does not inappropriately divert pharmacy NHS resources from the provision of routine patient care."
            },
            "type": "ListItem",
            "sequence_num": 106
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 7.2,
                "text": "Pharmacy should receive funding for providing a clinical trial service. This funding should reflect the workload and cover costs involved."
            },
            "type": "ListItem",
            "sequence_num": 107
        },
        {
            "data": {
                "is_heading": 0,
                "text": "For commercial trials, the most recent version of the NIHR study costing template should be completed / reviewed by the designated clinical trials pharmacist and regular invoicing subsequently prepared by a delegation staff member with relevant pharmacy details provided by the clinical trials pharmacy team."
            },
            "type": "ListItem",
            "sequence_num": 108
        },
        {
            "data": {
                "is_heading": 0,
                "text": "For non-commercial research the attribution of costs over and above usual NHS treatment costs are set out in the Department of Health document, attributing the costs of health and social care Research & Development (AcoRD). In some instances, there will be payments allocated by the sponsor for pharmacy and this should be invoiced for as above."
            },
            "type": "ListItem",
            "sequence_num": 109
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Where a clinical trial requires equipment over and above that already provided by the Trust, pharmacy should discuss the funding of that equipment with the trial sponsor and R&D."
            },
            "type": "ListItem",
            "sequence_num": 110
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 7.3,
                "text": "A delegated member of the pharmacy clinical trials team should maintain records of pharmacy activities undertaken per trial as well as funding received to aid staffing resource accounting and capacity planning."
            },
            "type": "ListItem",
            "sequence_num": 111
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 7.4,
                "text": "Clinical trials agreements (CTA) should not be signed without active pharmacy input prior to the CTA being agreed and signed. A copy of the CTA should be filed in the PSF for each clinical trial."
            },
            "type": "ListItem",
            "sequence_num": 112
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 7.5,
                "text": "A copy of the MHRA Good Clinical Practice Guide (\u2018The Grey Book') is available as a reference source in the site pharmacy departments."
            },
            "type": "ListItem",
            "sequence_num": 113
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 8.0,
                "text": "Prescription Charges"
            },
            "type": "ListItem",
            "sequence_num": 114
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 8.1,
                "text": "A prescription charge for IMP does not apply to patients involved in a clinical trial at a hospital site within the Mid and South Essex NHS Foundation Trust"
            },
            "type": "ListItem",
            "sequence_num": 115
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 9.0,
                "text": "Communication Within and Outside the Trust"
            },
            "type": "ListItem",
            "sequence_num": 116
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 9.1,
                "text": "The pharmacy clinical trials team should ensure an effective working relationship is established with the site investigators, research personnel, the R&D department and other support services, including the Clinical Research Network, to provide a responsive, high quality, comprehensive process for delivering the pharmacy clinical trials service."
            },
            "type": "ListItem",
            "sequence_num": 117
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 9.2,
                "text": "A good working relationship should also be established and maintained with sponsors, monitors, auditors and regulatory authorities."
            },
            "type": "ListItem",
            "sequence_num": 118
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 9.3,
                "text": "Pharmacy should foster a good working relationship with the R&D department and will be able to provide advice on issues such as:"
            },
            "type": "ListItem",
            "sequence_num": 119
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The source and quality of IMPs including comparators to be used;"
            },
            "type": "ListItem",
            "sequence_num": 120
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The cost of IMPs;"
            },
            "type": "ListItem",
            "sequence_num": 121
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The acceptability of the packaging and labelling of IMPs;"
            },
            "type": "ListItem",
            "sequence_num": 122
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Where the IMP is stored out of pharmacy, advice and risk assessment of the storage requirements for the IMPs;"
            },
            "type": "ListItem",
            "sequence_num": 123
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The regulatory approval process;"
            },
            "type": "ListItem",
            "sequence_num": 124
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The identification of possible clinical risk issues and how to address these where the use of an IMP is contrary to standard practice;"
            },
            "type": "ListItem",
            "sequence_num": 125
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The regulations and guidelines on GCP and Good Manufacturing Practice (GMP);"
            },
            "type": "ListItem",
            "sequence_num": 126
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Systems and procedures for internal clinical trials;"
            },
            "type": "ListItem",
            "sequence_num": 127
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Health and safety aspects of drug handling, dispensing and reconstitution;"
            },
            "type": "ListItem",
            "sequence_num": 128
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Correct use of medications used in non-CTIMP trials to ensure formulary status, prescribing conditions and availability in the trust;"
            },
            "type": "ListItem",
            "sequence_num": 129
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Legacy after trial closure, i.e. what access will patients have to continuing treatment."
            },
            "type": "ListItem",
            "sequence_num": 130
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 10.0,
                "text": "Set-up of a study"
            },
            "type": "ListItem",
            "sequence_num": 131
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 10.1,
                "text": "The pharmacy department clinical trial SOP for study set-up should be followed for more detail but encompasses the following:"
            },
            "type": "ListItem",
            "sequence_num": 132
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 10.2,
                "text": "The designated clinical trials pharmacist reviews each protocol, assesses the feasibility of the study, costs the work to be undertaken by pharmacy and, where appropriate, assesses the impact for pharmacy services."
            },
            "type": "ListItem",
            "sequence_num": 133
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 10.3,
                "text": "Where available, the Health Research Authority (HRA) single pharmacy technical review is used to facilitate the feasibility assessment."
            },
            "type": "ListItem",
            "sequence_num": 134
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 10.4,
                "text": "A designated member of the pharmacy clinical trials team should participate in the investigator meeting or the site selection visit and the site initiation visit. A pre-initiation meeting with pharmacy is helpful in order to agree the details of the pharmacy arrangements with the sponsor. Pharmacy staff use their professional expertise to review the protocol and explain the correct use and storage of any IMPs or non-IMPs to other healthcare professionals who may not be familiar with these."
            },
            "type": "ListItem",
            "sequence_num": 135
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 10.5,
                "text": "A risk assessment should be carried out as part of the feasibility process. Potential sources of risk include, but not limited to, storage, dispensing, reconstitution, clinical use, blinding and unblinding and treatment allocation, documentation, cost and post-trial access to medicines."
            },
            "type": "ListItem",
            "sequence_num": 136
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 10.6,
                "text": "IMPs must be manufactured in accordance with Good Manufacturing Practice (GMP) in a unit which holds a manufacturing authorisation - MIA (IMP) granted by the MHRA. IMPs must be labelled in accordance with Annex 13 and certified by a QP (IMP) for release. The distinction between manufacture and assembly and the circumstances where a QP (IMP) is not required are defined in The Medicines for Human Use (Clinical Trials) Regulations 2004. Regulation 37 provides an exemption from the need for hospitals participating in a clinical trial to hold and MIA (IMP) in order to assemble IMPs for use in that trial. A risk assessment determines whether such products require additional, clinical trial- specific labelling to comply with the regulations."
            },
            "type": "ListItem",
            "sequence_num": 137
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 10.7,
                "text": "The pharmacy clinical trials team requests samples of the packaging and labelling of IMPs from the sponsor in advance of local R&D approval of the clinical trial. Confirmation is sought from the sponsor that additional routine dispensing labels may be added to the product if required to comply with the hospital medicines management policy. Such labels are placed so as not to obscure any of the sponsors labelling. The pharmacy clinical trials team checks that the label on the IMP complies with Annex 13 and all other applicable legislation as appropriate."
            },
            "type": "ListItem",
            "sequence_num": 138
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 10.8,
                "text": "Where drug accountability forms and other associated forms are supplied by the sponsor, the pharmacy clinical trials team assesses their appropriateness for the data they are designed to capture and for their suitability for use within the pharmacy department. If the clinical trials pharmacist deems their in-house forms to be more suitable then this should be discussed and agreed with the sponsor."
            },
            "type": "ListItem",
            "sequence_num": 139
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 10.9,
                "text": "Local template prescription forms are used in preference to sponsor supplied prescription forms. This is to aid local recognition and consistency in the supply of IMP from the pharmacy, thereby minimising the risk of dispensing errors. The sponsor should be consulted as to whether or not their approval of the form is required prior to use. This applies also to electronic prescriptions."
            },
            "type": "ListItem",
            "sequence_num": 140
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 10.1,
                "text": "Upon collation of the necessary trial information, the specific Pharmacy Summary Sheet should be prepared prior to the treatment of the first patient."
            },
            "type": "ListItem",
            "sequence_num": 141
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 11.0,
                "text": "Approvals"
            },
            "type": "ListItem",
            "sequence_num": 142
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 11.1,
                "text": "Prior to the commencement of a clinical trial and the dispensing of any IMPs pharmacy must ensure the following are available:"
            },
            "type": "ListItem",
            "sequence_num": 143
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Appropriate regulatory documentation i.e. MHRA Clinical Trial Authorisation."
            },
            "type": "ListItem",
            "sequence_num": 144
        },
        {
            "data": {
                "is_heading": 0,
                "text": "A favourable opinion by REC."
            },
            "type": "ListItem",
            "sequence_num": 145
        },
        {
            "data": {
                "is_heading": 0,
                "text": "HRA approval."
            },
            "type": "ListItem",
            "sequence_num": 146
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Confirmation of capacity and capability from local R&D department."
            },
            "type": "ListItem",
            "sequence_num": 147
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 11.2,
                "text": "In addition to the above, trials involving systemic anti-cancer therapies are to be approved by the local SACT group."
            },
            "type": "ListItem",
            "sequence_num": 148
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 12.0,
                "text": "IMP Management"
            },
            "type": "ListItem",
            "sequence_num": 149
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 12.1,
                "text": "Clinical trials standard operating procedures are written approved and followed by the pharmacy clinical trials team."
            },
            "type": "ListItem",
            "sequence_num": 150
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 12.2,
                "text": "These SOPs are written and approved by the MSE clinical trials pharmacy group and reviewed every two years. In order to take into account variations in local practice, where necessary, a local appendix for each site is added to the SOP with site-specific instructions and local approval."
            },
            "type": "ListItem",
            "sequence_num": 151
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 12.3,
                "text": "In addition to these SOPs each clinical trial has a trial-specific procedure and the Pharmacy Summary Form which is placed at the front of each PSF. This must be read as part of the trial training programme before any member of staff is permitted to perform tasks for that trial."
            },
            "type": "ListItem",
            "sequence_num": 152
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 13.0,
                "text": "Receipt/delivery of IMP to pharmacy"
            },
            "type": "ListItem",
            "sequence_num": 153
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 13.1,
                "text": "All IMP must be delivered from the trial sponsor direct to the pharmacy department even if the IMP will ultimately be stored or maintained at ward level."
            },
            "type": "ListItem",
            "sequence_num": 154
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 13.2,
                "text": "Pharmacy goods receiving staff must receive appropriate training to ensure they are aware of the procedures for dealing with deliveries of IMP."
            },
            "type": "ListItem",
            "sequence_num": 155
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 14.0,
                "text": "Prescribing of IMP"
            },
            "type": "ListItem",
            "sequence_num": 156
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 14.1,
                "text": "Only authorised prescribers, as determined by the trial protocol, can prescribe IMP and they must be named on the trial delegation log. It is desirable for the pharmacy department to have a copy of the delegation log or access to a signature log."
            },
            "type": "ListItem",
            "sequence_num": 157
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 14.2,
                "text": "Although not a requirement of the Clinical Trials Regulations, it is Trust policy for IMPs to be prescribed on a study-specific clinical trial trust-headed prescription forms (paper or electronic) or a hospital drug chart as with other medicinal products."
            },
            "type": "ListItem",
            "sequence_num": 158
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 14.3,
                "text": "Hospital paper drug charts must be clearly annotated with \u2018CLINICAL TRIAL MEDICATION' together with the name and dosage details of the IMP. An equivalent is pre-set within JAC ePrescribing (where used). Every effort should be made to obtain the name of the clinical trial and sponsor contact details which should be entered in the patient notes."
            },
            "type": "ListItem",
            "sequence_num": 159
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 15.0,
                "text": "Supply of IMP from pharmacy"
            },
            "type": "ListItem",
            "sequence_num": 160
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 15.1,
                "text": "No supply of IMP is made unless either a prescription is presented which is signed by an authorised prescriber, or the IMP, by necessity, needs to be kept as a stock item in a ward setting."
            },
            "type": "ListItem",
            "sequence_num": 161
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 15.2,
                "text": "A clear system is in place between R&D and pharmacy to ensure prior notification of the need for dispensing/issuing an IMP. This benefits the service by ensuring time to arrange for suitably trained staff to be available for processing the prescription."
            },
            "type": "ListItem",
            "sequence_num": 162
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 15.3,
                "text": "Advance dispensing may take place providing the dispensed IMP remains in pharmacy until it is to be administered to. Alternatively is may be handed to the patient only where a suitable risk assessment is in place for it to be released to R&D staff prior to the day of patient visit/treatment."
            },
            "type": "ListItem",
            "sequence_num": 163
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 15.4,
                "text": "Each clinical trial has a pharmacy procedure with a pharmacy summary form, which is located at the front of the relevant PSF and must be followed at all times."
            },
            "type": "ListItem",
            "sequence_num": 164
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 15.5,
                "text": "Clinical trial subjects should be counselled on the correct use of the IMP. It should be agreed at the outset of the trial whether this is the responsibility of the research nurse or the pharmacist."
            },
            "type": "ListItem",
            "sequence_num": 165
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 16.0,
                "text": "Administering"
            },
            "type": "ListItem",
            "sequence_num": 166
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 16.1,
                "text": "Research nurses responsible for the administration of IMP to patients must follow the trial protocol instructions but should also ensure the administration is in accordance with Trust policies for the Administration of Medicines to Inpatients, the Injectable Medicines policy and the Cytotoxic Medicines policy (or equivalents, where appropriate). Staff responsible for the safe administration of Systemic Anti-Cancer Therapy (SACT) must have completed a SACT Competency Passport."
            },
            "type": "ListItem",
            "sequence_num": 167
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 16.2,
                "text": "Registered Nursing staff responsible for the administration of IMP to patients admitted as in-patients must follow the trust Administration of Medicines to Inpatients, the Injectable Medicines policy and the Cytotoxic Medicines policy (or equivalents, where appropriate). These policies refer nursing staff to contact pharmacy and/or R&D who will advise them of the following:"
            },
            "type": "ListItem",
            "sequence_num": 168
        },
        {
            "data": {
                "is_heading": 0,
                "text": "When patients on clinical trial medication are admitted into hospital, the investigator should be contacted at the earliest opportunity. Unless stipulated otherwise by the protocol, or due to the overriding clinical condition of the patient, continuity of treatment should be maintained."
            },
            "type": "ListItem",
            "sequence_num": 169
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ward staff should contact pharmacy and/or the R&D department to inform them and obtain further advice. Where an electronic alert system is available, this should be utilised for highlighting patients' who are participating in clinical trials."
            },
            "type": "ListItem",
            "sequence_num": 170
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ward staff and research practitioners should be aware of information relating to the IMPs administration, monitoring for adverse drug reactions and side effects, as well as how to report these to the investigator."
            },
            "type": "ListItem",
            "sequence_num": 171
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Sufficient information about the IMP should be available to the staff and/or patient to enable identification and correct use of the product."
            },
            "type": "ListItem",
            "sequence_num": 172
        },
        {
            "data": {
                "is_heading": 0,
                "text": "IMPs should not be omitted except when deemed necessary by the treating consultant or for clinical reasons as defined in the individual study protocol."
            },
            "type": "ListItem",
            "sequence_num": 173
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The nurse looking after the patient is responsible for ensuring that IMP is administered and any deviations are documented accurately. The research team and pharmacy should be contacted in these circumstances."
            },
            "type": "ListItem",
            "sequence_num": 174
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ward staff should have access to the investigators and research teams contact details. This is to ensure the relevant personnel can be contacted when required, to disseminate information regarding a study and/or participant."
            },
            "type": "ListItem",
            "sequence_num": 175
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Standard hospital stock must never be used as a substitute for IMP even if the name of the medication appears to be the same as regular licensed medication."
            },
            "type": "ListItem",
            "sequence_num": 176
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 16.3,
                "text": "Where it is agreed that the patient should receive IMP during their inpatient stay, this should be clearly documented in the patient notes and the drug chart entry annotated with CLINICAL TRIAL MEDICATION."
            },
            "type": "ListItem",
            "sequence_num": 177
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 16.4,
                "text": "Second checkers for all IMPs must be a qualified nurse with relevant training. All medicines must be checked, administered and signed for by two qualified nurses or midwives."
            },
            "type": "ListItem",
            "sequence_num": 178
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 17.0,
                "text": "Safety Monitoring"
            },
            "type": "ListItem",
            "sequence_num": 179
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 17.1,
                "text": "Records, including prescription charts should be regularly audited by relevant pharmacy staff, to ensure compliance. They will also be subject to external audit by several bodies including, but not limited to, the Medicines and Healthcare products Regulatory Agency (MHRA), independent clinical trials monitors and the Trust's Research and Development Department staff."
            },
            "type": "ListItem",
            "sequence_num": 180
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 17.2,
                "text": "The clinical trial SOP for Audit, Monitoring, Inspection and GCP Compliance should be followed."
            },
            "type": "ListItem",
            "sequence_num": 181
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 17.3,
                "text": "Receipt, dispensing, issue, administration and disposal of all IMPs must be accurately documented to facilitate reconciliation and to comply with Good Clinical Practice (GCP) and statutory requirements."
            },
            "type": "ListItem",
            "sequence_num": 182
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 18.0,
                "text": "Incident Reporting"
            },
            "type": "ListItem",
            "sequence_num": 183
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 18.1,
                "text": "All complaints, incidents and dispensing errors must be reported in accordance with the relevant Trust policies and specific clinical trial protocol requirements."
            },
            "type": "ListItem",
            "sequence_num": 184
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 18.2,
                "text": "The clinical trial SOP for Recording and Monitoring of Complaints, Incidents and Dispensing Errors should be followed."
            },
            "type": "ListItem",
            "sequence_num": 185
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 19.0,
                "text": "Training Requirements"
            },
            "type": "ListItem",
            "sequence_num": 186
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 19.1,
                "text": "Individual staff members must ensure GCP competence commensurate with their roles and responsibilities in relation to CTIMPs. Those pharmacy staff carrying out tasks that are part of their normal role must have an awareness of GCP."
            },
            "type": "ListItem",
            "sequence_num": 187
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 19.2,
                "text": "Individual training requirements are assessed by the lead clinical trials pharmacist in accordance with the NIHR Delegation and Training Decision Aid."
            },
            "type": "ListItem",
            "sequence_num": 188
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 19.3,
                "text": "The clinical trial SOP for Training of Pharmacy Personnel should be followed."
            },
            "type": "ListItem",
            "sequence_num": 189
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 19.4,
                "text": "Staff responsible for the safe administration of Systemic Anti-Cancer Therapy (SACT) must have completed a SACT Competency Passport."
            },
            "type": "ListItem",
            "sequence_num": 190
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 20.0,
                "text": "Monitoring and Audit"
            },
            "type": "ListItem",
            "sequence_num": 191
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Each document must outline the Trust's process of monitoring compliance with,"
            },
            "type": "ListItem",
            "sequence_num": 192
        },
        {
            "data": {
                "is_heading": 0,
                "text": "and the effectiveness of the document's main points."
            },
            "type": "ListItem",
            "sequence_num": 193
        },
        {
            "type": "table",
            "sequence_num": 194,
            "data": {
                "num_rows": 3,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Aspect of compliance or effectiveness being monitored"
                    },
                    {
                        "text": "Monitoring Method"
                    },
                    {
                        "text": "Individual department responsible for the monitoring"
                    },
                    {
                        "text": "Frequency of the monitoring activity"
                    },
                    {
                        "text": "Group / Committee / forum which will receive the findings/monitoring report"
                    },
                    {
                        "text": "Committee / individual responsible for ensuring the actions are completed"
                    },
                    {
                        "text": "Individual study compliance"
                    },
                    {
                        "text": "Inspection by Sponsors"
                    },
                    {
                        "text": "Research and Developme nt Department. Pharmacy clinical trials team."
                    },
                    {
                        "text": "Variable \u2013 specified in trial protocol"
                    },
                    {
                        "text": "Research and Development Department"
                    },
                    {
                        "text": "Chair of the Research and Development Committee or equivalent. Lead clinical trials pharmacist."
                    },
                    {
                        "text": "Adherence to Good Clinical Practice (GCP)"
                    },
                    {
                        "text": "Inspection by MHRA"
                    },
                    {
                        "text": "Research and Developme nt department"
                    },
                    {
                        "text": "Variable \u2013 as specified by MHRA. (GCP training is"
                    },
                    {
                        "text": "Research and Development Department"
                    },
                    {
                        "text": "Chair of the Research and Development Committee or equivalent"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 195,
            "data": {
                "num_rows": 3,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "valid for 2 years)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Adherence to Pharmacy procedures"
                    },
                    {
                        "text": "Local clinical trials team audit"
                    },
                    {
                        "text": "Department of Pharmacy"
                    },
                    {
                        "text": "Ongoing & following a reported incident."
                    },
                    {
                        "text": "Pharmacy directorate board"
                    },
                    {
                        "text": "Chief pharmacist"
                    },
                    {
                        "text": "Completed GCP Training"
                    },
                    {
                        "text": "Log of GCP training records."
                    },
                    {
                        "text": "Department of Pharmacy Research and Developme nt Department"
                    },
                    {
                        "text": "Monthly"
                    },
                    {
                        "text": "Research and Development Department"
                    },
                    {
                        "text": "Chair of the Research and Development Committee or equivalent Lead clinical trials pharmacist"
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 21.0,
                "text": "Approval and Implementation"
            },
            "type": "ListItem",
            "sequence_num": 196
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 21.1,
                "text": "This policy has been reviewed and approved by the Medicines Optimisation Committee (or equivalent), overseen by pharmacy, across the mse group of hospitals. This will be implemented with immediate effect from its agreement date. This document will be available electronically on the Trust intranet. Advice and support on the implementation of this policy is available via the site pharmacy clinical trials team within the department of pharmacy."
            },
            "type": "ListItem",
            "sequence_num": 197
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 22.0,
                "text": "References"
            },
            "type": "ListItem",
            "sequence_num": 198
        },
        {
            "data": {
                "is_heading": 0,
                "text": "MHRA. (2012). Good Clinical Practice Guide."
            },
            "type": "ListItem",
            "sequence_num": 199
        },
        {
            "data": {
                "is_heading": 0,
                "text": "NPCTAG (2019) Professional Guidance on Pharmacy Services for Clinical Trials v2.1."
            },
            "type": "ListItem",
            "sequence_num": 200
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Department of Health. (2012). Attributing the costs of health and social care Research & Development (AcoRD)."
            },
            "type": "ListItem",
            "sequence_num": 201
        },
        {
            "data": {
                "is_heading": 0,
                "text": "UK Oncology Nursing Society (UKONS). (2017). Competency Passport for the Safe Handling and Administration of Systemic Anti-Cancer Therapy (SACT)."
            },
            "type": "ListItem",
            "sequence_num": 202
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 23.0,
                "text": "Equality Impact Assessment"
            },
            "type": "ListItem",
            "sequence_num": 203
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 23.1,
                "text": "This policy has been the subject of an Equality Impact Assessment. The output of the assessment demonstrates that no one as a consequence of this policy is placed at a disadvantage over others."
            },
            "type": "ListItem",
            "sequence_num": 204
        },
        {
            "data": {
                "is_heading": 0,
                "text": "(Refer to appendix 1)"
            },
            "type": "ListItem",
            "sequence_num": 205
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Safe Handling, Effective Use and Management of Investigational Medicinal Products (IMPs) Policy/ MSEPO- 20204 / version 1.0"
            },
            "type": "ListItem",
            "sequence_num": 206
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 23.0,
                "text": "Page  of"
            },
            "type": "ListItem",
            "sequence_num": 207
        },
        {
            "data": {
                "is_heading": 1,
                "text": "This is an uncontrolled copy of this policy. To check if this is a copy of the latest version please view this policy on-line on StaffNet"
            },
            "type": "ListItem",
            "sequence_num": 208
        },
        {
            "data": {
                "is_heading": 1,
                "text": "Safe Handling, Effective Use and Management of Investigational Medicinal Products (IMPs) Policy/ MSEPO-20204 / version 1.0 Appendix 1: Preliminary Equality Analysis"
            },
            "type": "ListItem",
            "sequence_num": 209
        },
        {
            "data": {
                "is_heading": 1,
                "text": "This assessment relates to: Safe Handling, Effective Use and Management of Investigational Medicinal Products (IMPs) Policy/ MSEPO20204"
            },
            "type": "ListItem",
            "sequence_num": 210
        },
        {
            "type": "table",
            "sequence_num": 211,
            "data": {
                "num_rows": 9,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "A change in a service to patients"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to an existing policy"
                    },
                    {
                        "text": "Y"
                    },
                    {
                        "text": "A change to the way staff work"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A new policy"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Something else (please give details)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Questions"
                    },
                    {
                        "text": "Answers"
                    },
                    {
                        "text": "What are you proposing to change?"
                    },
                    {
                        "text": "Content of policy"
                    },
                    {
                        "text": "Why are you making this change? (What will the change achieve?)"
                    },
                    {
                        "text": "Updated information. Specific SOPs now available so some content can be removed from this policy. To make applicable to all sites."
                    },
                    {
                        "text": "Who benefits from this change and how?"
                    },
                    {
                        "text": "Staff involved in the management of IMP"
                    },
                    {
                        "text": "Is anyone likely to suffer any negative impact as a result of this change? If no, please record reasons here and sign and date this assessment. If yes, please complete a full EIA."
                    },
                    {
                        "text": "No. The changes do not affect the service provided except to provide greater clarity."
                    },
                    {
                        "text": "a) Will you be undertaking any consultation as part of this change? b) If so, with whom?"
                    },
                    {
                        "text": "Yes. Refer to pages 1& 2"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "text": "Preliminary analysis completed by:"
            },
            "type": "ListItem",
            "sequence_num": 212
        },
        {
            "type": "table",
            "sequence_num": 213,
            "data": {
                "num_rows": 1,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Name"
                    },
                    {
                        "text": "Emma Cannon"
                    },
                    {
                        "text": "Job Title"
                    },
                    {
                        "text": "Lead Pharmacist Clinical Trials (MEHT)"
                    },
                    {
                        "text": "Date"
                    },
                    {
                        "text": "July 2019"
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 19.0,
                "text": "Page  of"
            },
            "type": "ListItem",
            "sequence_num": 214
        },
        {
            "data": {
                "is_heading": 1,
                "text": "This is an uncontrolled copy of this policy. To check if this is a copy of the latest version please view this policy on-line on StaffNet"
            },
            "type": "ListItem",
            "sequence_num": 215
        }
    ]
}